Killing of human lung cancer cells using a new [111In]bleomycin complex [111In]BLMC.
The ability of a [111In]bleomycin complex [( 111In]BLMC) to kill five cell lines of human lung cancer (small cell lung cancer) was investigated. Cells were exposed to either 0.9% NaCl, [111In]Cl3, BLM, [111In]BLMC, nonradioactive InCl3, or In-BLMC for 60 minutes, plated in soft agarose, and assessed for colony formation. [111In]BLMC (40-200 microCi carried by 15-25 micrograms BLM/ml) was more cytotoxic than BLM (15-25 micrograms BLM/ml) by a factor of 1.6-5.3 for five cell lines. The percent survival of N417 cells was 28.4 for [111In]BLMC (40 microCi/15 micrograms BLM/ml) and 54.3 for BLM (15 micrograms/ml); 1.9 for [111In]BLMC (200 microCi/25 micrograms BLM/ml), and 10.0 for BLM (25 micrograms/ml). 111InCl3 (200 microCi/ml) and nonradioactive InCl3 failed to inhibit colony formation. The new [111In]BLMC may be useful for therapy of some lung cancer patients.
Hou
D Y
DY
Division of Developmental Therapeutics, University of Maryland Cancer Center, Baltimore 21201.
Hamburger
A W
AW
Beach
J L
JL
Maruyama
Y
Y
D001345:Autoradiography; D001761:Bleomycin / Q000494:pharmacology* / Q000031:analogs & derivatives; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007205:Indium Radioisotopes; D008175:Lung Neoplasms / Q000473:pathology*; D009942:Organometallic Compounds / Q000494:pharmacology*; D011829:Radiation Dosage; D013997:Time Factors; D014407:Tumor Cells, Cultured
D007205:Indium Radioisotopes; D009942:Organometallic Compounds; C047120:indium-bleomycin; D001761:Bleomycin